1. Home
  2. Live Updates
  3. Medigene ag stock exchange

Live Breaking News & Updates on Medigene ag stock exchange

Stay informed with the latest breaking news from Medigene ag stock exchange on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Medigene ag stock exchange and stay connected to the pulse of your community

Medigene AG to participate at BIO International in Boston

Planegg/Martinsried, May 30, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO... | May 30, 2023

Boston , Massachusetts , United-states , Pamela-keck , Planegg-martinsried , Hongsheng-sciences , International-convention , Prime-standard , Lifesci-advisors , Precision-pairing , Medigene-ag-stock-exchange , Ews

Medigene AG Expands Patent Portfolio for its End-to-End Platform

Planegg/Martinsried, May 22, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today that the... | May 22, 2023

Munich , Bayern , Germany , China , Hongsheng , Hubei , United-states , Japan , Pamela-keck , Planegg-martinsried , Hongsheng-sciences , Japan-patent-office

Medigene : BioEquity Präsentation 14.-16. Mai, 2023

Pioneering Differentiated TCR-T Therapies for Cancer Patients




Bio€quity 2023





Forward... | May 19, 2023

While-the-company , Forward-looking-statement , Medigene-ag-stock-exchange , Ews , Nformation , Ress-release , Ioneering , Ifferentiated , Herapies , Or , Ancer-mdg1-de000a1x3w00

Medigene AG to present at upcoming investor conferences

Planegg/Martinsried, May 8, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the following... | May 8, 2023

Ireland , Dublin , Germany , Pamela-keck , Planegg-martinsried , Mc-services , Prime-standard , Spring-conference , Medigene-ag-stock-exchange , Ews , Nformation , Ress-release

Medigene expands end-to-end technology platform through worldwide, exclusive license of a CD40L-CD28 Costimulatory Switch Receptor further enhancing potential to treat solid tumors

Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T... | May 2, 2023

Munich , Bayern , Germany , Martinsried , Dolores-schendel , Pamela-keck , Hongsheng-sciences , Prime-standard , Helmholtz-munich , Chief-scientific , Precision-pairing , Programmed-death-ligand

Medigene AG to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Martinsried/Munich, April 27, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the... | April 27, 2023

Andrea-coluccio , Doloresj-schendel , Sebastian-karg , Pamela-keck , Dimitri-frishmann , Hongsheng-sciences , Globenewswire-inc , Prime-standard , Webtool-empowered , Machine-learning , Precision-pairing , Medigene-ag-stock-exchange

New data presented at AACR Annual Meeting demonstrates significantly enhanced anti-solid tumor effects of T cells co-expressing an optimal affinity TCR targeting NY-ESO-1 and a PD1-41BB co-stimulatory switch receptor (MDG1015)

Martinsried/Munich, April 18, 2023, Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents preclinical... | April 18, 2023

Florida , United-states , Orlando , New-york , Pamela-keck , Hongsheng-sciences , Prime-standard , Polyfunctional-strength-index , Chief-executive-officer , Precision-pairing , Medigene-ag-stock-exchange , Ews

Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development

Martinsried/Munich, April 04, 2023. Medigene AG is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dr.... | April 4, 2023

Dolores-schendel , Pamela-keck , Hongsheng-sciences , Therapy-development , Prime-standard , Chief-scientific-officer , Solid-tumors-summit , Study-spotlight , Introducing-innovations , Each-step , Precision-pairing , Medigene-ag-stock-exchange

Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene's proprietary T cell receptors in novel cell constructs

Martinsried/Munich, April 3, 2023. Medigene AG , an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, and the National... | April 3, 2023

Dolores-schendel , Lawrence-samelson , Pamela-keck , Molecular-biology-of-the-center , Laboratory-of-cellular , National-institutes-of-health , Cancer-research , National-cancer-institute , Hongsheng-sciences , Prime-standard , National-institutes , Molecular-biology

Medigene : Annual Report 2022 Presentation

Pioneering Differentiated TCR-T Therapies for Cancer Patients


FY 2022 Financial Results and Corporate Update



Forward Looking... | March 30, 2023

Germany , United-states , San-diego , California , Munich , Bayern , Hongsheng-sciences , Development-optimization , While-the-company , Patient-immune-monitoring-development-optimization , E-proprietary-technology-platform-advanced